Laboratoire en 1ère ligne contre les maladies neurologiques

« Une technologie de rupture déclinable dans de nombreuses pathologies neurologiques »

> Communiqués de presse

Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy
Télécharger le PDF (428 Ko)

Theranexus and its partners receive support from the FUI (French Inter-ministry Fund) for their project, Cx-COG
Télécharger le PDF (149 Ko)

Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)
Télécharger le PDF (174 Ko)

Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102
Télécharger le PDF (111 Ko)

Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders
Télécharger le PDF (556 Ko)

Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies
Télécharger le PDF (567 Ko)

Theranexus lève avec succès 3,6 M€ en amorçage
Télécharger le PDF (147 Ko)